Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-29
DOI
10.1038/s41467-017-00450-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
- (2015) P. N. Lara et al. CLINICAL CANCER RESEARCH
- Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
- (2015) CLAIRE CRAFTER et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
- (2015) Heiner Koch et al. JOURNAL OF PROTEOME RESEARCH
- Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
- (2015) Chee-Seng Tan et al. LANCET ONCOLOGY
- AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
- (2015) R. Ribas et al. MOLECULAR CANCER THERAPEUTICS
- Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
- (2015) E. M. Tricker et al. Cancer Discovery
- Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
- (2015) Shengzhi Xie et al. Oncotarget
- BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
- (2015) Niki Karachaliou et al. Scientific Reports
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling
- (2014) Andrea Köhler et al. Molecular Cancer
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway
- (2014) J J Havel et al. ONCOGENE
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Role of PRAS40 in Akt and mTOR signaling in health and disease
- (2012) Claudia Wiza et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers
- (2011) H. W. Cheung et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
- (2009) Guang Jin et al. LUNG CANCER
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now